Get the Daily Brief
Latest Biotech News
Qiagen buys Parse to add scalable single‑cell capabilities
Qiagen agreed to acquire Parse Biosciences for $225 million in cash plus up to $55 million in milestones, accelerating Qiagen’s entrance into high‑throughput, instrument‑free single‑cell genomics....
Non‑surgical cell‑electronics brain implants modulate targets in mice
MIT researchers published a Nature Biotechnology paper describing microscopic, wireless bioelectronic devices fused with immune cells that autonomously home to inflamed brain regions after...
Braveheart nets $185M to advance Hengrui‑licensed heart drug
Braveheart Bio closed a $185 million financing led by top life‑science investors to fund registration‑enabling studies of a small‑molecule candidate licensed from Jiangsu Hengrui for hypertrophic...
Metsera melee: Novo bids $10B while Pfizer sues
Novo Nordisk raised its offer for obesity biotech Metsera to as much as $10 billion, and the company’s board has flagged Novo’s proposal as a superior transaction. Simultaneously, Pfizer filed...
Blackstone banks Merck’s ADC push — $700M risk deal
Blackstone Life Sciences agreed to provide roughly $700 million to underwrite Merck’s development of a Trop2-targeting antibody‑drug conjugate, shifting a large portion of clinical and commercial...
FDA clears UCB’s Kygevvi — first therapy for TK2 deficiency
The U.S. Food and Drug Administration approved UCB’s Kygevvi for thymidine kinase 2 (TK2) deficiency in adults and children with symptom onset by age 12, marking the first approved therapy for...
Sarepta setback — Duchenne confirmatory trial fails; company to press FDA
A long‑ awaited confirmatory trial for Sarepta’s exon‑skipping therapies in Duchenne muscular dystrophy failed to meet its primary endpoint, the company announced, dealing a significant regulatory...
FDA rebuffs Biohaven’s RWE submission — troriluzole hit with CRL
The FDA issued a complete response letter rejecting Biohaven’s application for troriluzole in spinocerebellar ataxia after the company relied heavily on real‑world evidence (RWE) and an external...
Braveheart raises $185M to challenge HCM market — Biogen chair on board
Braveheart Bio closed a $185 million Series A to launch global registration‑enabling trials for a hypertrophic cardiomyopathy (HCM) candidate licensed from Jiangsu Hengrui. The funding round...
Azalea raises $82M — Doudna spinoff targets single‑shot in vivo CAR‑T
A startup spun out of Jennifer Doudna’s lab has closed an $82 million financing to develop in vivo CAR‑T medicines that aim to reprogram patients’ immune cells inside the body with a single...
Qiagen buys Parse Biosciences — push into single‑cell market
Qiagen agreed to acquire Parse Biosciences for $225 million in cash plus up to $55 million in milestones, a move to bring instrument‑free single‑cell sample‑prep into its portfolio. The...
Tempus AI readies for MRD reimbursement — Q3 revenue jumps 85%
Tempus reported an 85% year‑over‑year revenue jump in Q3 as the company positions its MRD (minimal residual disease) tests for reimbursement and seeks FDA submissions for multiple assays....
FDA turmoil: CDER chief resigns amid probe, critics warn credibility erodes
George Tidmarsh resigned as director of FDA’s Center for Drug Evaluation and Research after being placed on administrative leave amid an internal probe into his conduct, according to reporting in...
Metsera M&A melee: Novo raises bid to $10 billion
Novo Nordisk and Pfizer escalated a takeover duel for obesity biotech Metsera this week, with Novo increasing its proposal to as much as $10 billion and Pfizer responding with a raised...
FDA turmoil: CDER chief exits amid probe
The FDA’s drug review center lost its director after George Tidmarsh was placed on administrative leave and then resigned as the Department of Health and Human Services opened a probe into his...
UniQure stumble: FDA shifts on Huntington’s gene therapy
UniQure disclosed that the FDA no longer appears to view its Phase I/II AMT‑130 data as sufficient to support a Biologics License Application, reversing earlier signals that had encouraged the...
Sarepta confirmatory miss – Duchenne trial fails primary endpoint
Sarepta Therapeutics reported that its long‑awaited ESSENCE confirmatory trial of two exon‑skipping drugs missed the primary endpoint, producing results that the company described as influenced by...
FDA rejects Biohaven’s RWE bid for troriluzole
The FDA issued a complete response letter to Biohaven's submission for troriluzole in a neurological indication, ruling that the real‑world evidence (RWE) and externally controlled analyses failed...
Braveheart raises $185M to advance HCM candidate
Braveheart Bio closed a $185 million financing to launch registration‑enabling studies of a hypertrophic cardiomyopathy candidate licensed from Jiangsu Hengrui. The Series A attracted top biotech...
Qiagen to buy Parse Biosciences for single‑cell push
Qiagen agreed to acquire Parse Biosciences for $225 million in cash plus up to $55 million in milestones, folding an instrument‑free single‑cell sample prep technology into Qiagen’s sample and...